EA202090892A1 - MODIFIED GUIDE RNA Cpf1 - Google Patents

MODIFIED GUIDE RNA Cpf1

Info

Publication number
EA202090892A1
EA202090892A1 EA202090892A EA202090892A EA202090892A1 EA 202090892 A1 EA202090892 A1 EA 202090892A1 EA 202090892 A EA202090892 A EA 202090892A EA 202090892 A EA202090892 A EA 202090892A EA 202090892 A1 EA202090892 A1 EA 202090892A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cpf1
nucleic acid
guide rna
modified guide
present
Prior art date
Application number
EA202090892A
Other languages
Russian (ru)
Inventor
Кунвоо Ли
Original Assignee
Дженедит Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженедит Инк. filed Critical Дженедит Инк.
Priority claimed from PCT/US2018/054027 external-priority patent/WO2019070762A1/en
Publication of EA202090892A1 publication Critical patent/EA202090892A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к нуклеиновой кислоте, содержащей cr-РНК Cpf1, последовательность процессинга у 5'-конца cr-РНК Cpf1 и последовательность удлинения у 5'-конца последовательности процессинга. Настоящее изобретение также относится к композиции, содержащей нуклеиновую кислоту, носитель и, необязательно, Cpf1. Кроме того, настоящее изобретение относится к способу генетической модификации эукариотической клетки-мишени, включающему контактирование эукариотической клетки-мишени с нуклеиновой кислотой или с композицией для генетической модификации нуклеиновой кислоты-мишени в клетке.The present invention relates to a nucleic acid comprising a Cpf1 cr-RNA, a processing sequence at the 5'-end of the Cpf1 cr-RNA and an extension sequence at the 5'-end of the processing sequence. The present invention also provides a composition comprising a nucleic acid, a carrier and, optionally, Cpf1. In addition, the present invention relates to a method for genetically modifying a eukaryotic target cell, comprising contacting the eukaryotic target cell with a nucleic acid or a composition for genetically modifying a target nucleic acid in a cell.

EA202090892A 2018-07-12 2018-10-02 MODIFIED GUIDE RNA Cpf1 EA202090892A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697327P 2018-07-12 2018-07-12
PCT/US2018/054027 WO2019070762A1 (en) 2017-10-02 2018-10-02 Modified cpf1 guide rna

Publications (1)

Publication Number Publication Date
EA202090892A1 true EA202090892A1 (en) 2020-08-06

Family

ID=72235079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090892A EA202090892A1 (en) 2018-07-12 2018-10-02 MODIFIED GUIDE RNA Cpf1

Country Status (1)

Country Link
EA (1) EA202090892A1 (en)

Similar Documents

Publication Publication Date Title
MX2020003339A (en) Modified cpf1 guide rna.
EA201991555A1 (en) COMPOSITIONS AND METHODS FOR STRENGTHENING OR INCREASING PRODUCTS IFN I TYPE
BR112018076190A2 (en) orthologs and crispr type vi systems
EA202090290A1 (en) APPLICATION OF PROTEIN Cas, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT
CY1121657T1 (en) METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND FOR RNA-DIRECTED REGULATION OF TRANSCRIPTION
EA201990861A1 (en) RNA-GUIDED MODIFICATING NUCLEIC ACIDS ENZYMES AND METHODS OF APPLICATION
EA201890565A1 (en) COMPOSITIONS AND METHODS OF IMPROVING SPECIFICITY IN GENOMIC ENGINEERING WITH THE USE OF RNA-DIRECTED ENDONUCLEAS
BR112019006388A2 (en) rna-guided nucleic acid modifying enzymes and methods of using them
WO2018015936A3 (en) Methods and compositions for modifying genomic dna
EA201992001A1 (en) COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
MX2018001617A (en) Engineered crispr-cas9 compositions and methods of use.
BR112016014022A2 (en) anti-cd3 antibodies, isolated nucleic acid, vector, host cell, anti-cd3 antibody production method, immunoconjugate, composition, use of anti-cd3 antibody, treatment methods, methods of enhancing immune function and kit
EP3699280A3 (en) Novel cas9 systems and methods of use
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
EA201291024A1 (en) COMPOSITIONS OF ENDORIBONUCLEAS AND METHODS OF THEIR USE
WO2018170614A8 (en) New technique for genomic large fragment direct cloning and dna multi-molecular assembly
EA201891629A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING THE EFFICIENCY OF TARGETED MODIFICATION OF GENES WITH THE APPLICATION OF MEDIATED OLIGONUCLEOTIDE REPAIR GENES
EA201791681A1 (en) METHOD OF SITE-DIRECTED MODIFICATION OF A WHOLE PLANT BY MEANS OF TRANSIENT EXPRESSION OF A GENE
EA202090067A3 (en) METHOD FOR OBTAINING RECOMBINANT ADAMTS13 IN CELL CULTURE
MX2022005328A (en) Compositions and methods for rna-encoded dna-replacement of alleles.
ATE512228T1 (en) INDUCABLE EXPRESSION SYSTEMS
DE50311850D1 (en) CONSTRUCTS AND METHODS FOR REGULATING GENE EXPRESSION
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
MX2022007575A (en) Anti-cd73 antibodies and uses thereof.
EA202190454A1 (en) NEW CRISPR-ASSOCIATED PROTEIN AND ITS APPLICATIONS